Mitochondrial DNA subhaplogroups L0a2 and L2a modify susceptibility to peripheral neuropathy in Malawian adults on stavudine containing highly active antiretroviral therapy

Journal of Acquired Immune Deficiency Syndromes

Volumn 63, Issue 5, 2013, Pages 647-652

  Kampira, Elizabeth ^a,b   Kumwenda, Johnstone ^b   Van Oosterhout, Joep J ^b   Dandara, Collet ^a  

^a UNIVERSITY OF CAPE TOWN   (South Africa)

^b UNIVERSITY OF MALAWI   (Malawi)

Author keywords

MtDNA; Peripheral neuropathy; Stavudine; Subhaplogroup; Toxicities

Indexed keywords

CD4 ANTIGEN; CREATININE; MITOCHONDRIAL DNA; STAVUDINE;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ARTICLE; CROSS-SECTIONAL STUDY; DISEASE PREDISPOSITION; FEMALE; GENETIC VARIABILITY; HAPLOTYPE; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MAJOR CLINICAL STUDY; MALAWI; MALE; NUCLEOTIDE SEQUENCE; PERIPHERAL NEUROPATHY; PRIORITY JOURNAL; VIRUS LOAD;

ADULT; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; CD4 LYMPHOCYTE COUNT; CREATININE; CROSS-SECTIONAL STUDIES; DISEASE SUSCEPTIBILITY; DNA, MITOCHONDRIAL; FEMALE; GENETIC VARIATION; HAPLOTYPES; HIV INFECTIONS; HUMANS; MALAWI; MALE; MIDDLE AGED; PERIPHERAL NERVOUS SYSTEM DISEASES; STAVUDINE; VIRAL LOAD;

EID: 84883449878     PISSN: 15254135     EISSN: 10779450     Source Type: Journal    
DOI: 10.1097/QAI.0b013e3182968ea5     Document Type: Article

References (35)

1. Brinley FJ Jr, Pardo CA,Verma A.Human immunodeficiency virus and the peripheral nervous system workshop. Arch Neurol. 2001;58:1561-1566.
2. van Oosterhout JJ, Mallewa J, Kaunda S, et al. Stavudine toxicity in adult longer-term ART patients in Blantyre, Malawi. PLoS One. 2012;7:e42029.
3. Berger AR, Arezzo JC, Schaumburg HH, et al. 2',3'-dideoxycytidine (ddC) toxic neuropathy: a study of 52 patients. Neurology. 1993;43: 358-362.
4. Cui L, Locatelli L, Xie M-Y, et al. Effect of nucleoside analogs on neurite regeneration and mitochondrial DNA synthesis in PC-12 Cells. J Pharmacol Exp Ther. 1997;280:1228-1234.
5. Bailey CM, Kasiviswanathan R, Copeland WC, et al. R964C Mutation of DNA Polymerase {gamma} imparts increased stavudine toxicity by decreasing nucleoside analog discrimination and impairing polymerase activity. Antimicrob Agents Chemother. 2009;53:2610-2612.
6. Kakuda TN. Pharmacology of nucleoside and nucleotide reverse transcriptase inhibitor-induced mitochondrial toxicity. Clin Ther. 2000;22: 685-708.
7. Lewis W, Day BJ, Copeland WC. Mitochondrial toxicity of NRTI antiviral drugs: an integrated cellular perspective. Nat Rev Drug Discov. 2003;2:812-822.
8. Hulgan T, Haas DW, Haines JL, et al. Mitochondrial haplogroups and peripheral neuropathy during antiretroviral therapy: an adult AIDS clinical trials group study. AIDS. 2005;19:1341-1349.
9. Chen YS, Torroni A, Excoffier L, et al. Analysis of mtDNA variation in African populations reveals the most ancient of all human continentspecific haplogroups. Am J Hum Genet. 1995;57:133-149.
10. Behar Doron M, van Oven M, Rosset S, et al. A Copernican reassessment of the human mitochondrial DNA tree from its root. Am J Hum Genet. 2012;90:675-684.
11. Herrnstadt C, Elson JL, Fahy E, et al. Reduced-median-network analysis of complete mitochondrial DNA coding-region sequences for the major African, Asian, and European haplogroups. Am J Hum Genet. 2002;70: 1152-1171.
12. van Oven M, Kayser M. Updated comprehensive phylogenetic tree of global human mitochondrial DNA variation. Hum Mutat. 2009;30: E386-E394.
13. Anderson-Mann S. Phylogenetic and Phylogeographic Analysis of African Mitochondrial DNA Variation [thesis]. Leeds, England: University of Leeds; 2006.
14. Gonder MK, Mortensen HM, Reed FA, et al. Whole-mtDNA genome sequence analysis of ancient African lineages. Mol Biol Evol. 2007;24: 757-768.
15. Tishkoff SA, Gonder MK, Henn BM, et al. History of click-speaking populations of Africa inferred from mtDNA and Y chromosome genetic variation. Mol Biol Evol. 2007;24:2180-2195.
16. Canter JA, Haas DW, Kallianpur AR, et al. The mitocondrial pharmacogenomics of haplogroup T: MTND2&z.ast;LHON4917G and antiretroviral therapy-associated peripheral neuropathy. Pharmacogenomics J. 2007;8: 71-77.
17. National Kidney Foundation. K/DOQI clinical practice guidelines for chronic Kidney disease: evaluation, classification, and stratification. Am J Kidney Dis. 2002;39:S1-S266
18. Ramos A, Santos C, Alvarez L, et al. Human mitochondrial DNA complete amplification and sequencing: a new validated primer set that prevents nuclear DNA sequences of mitochondrial origin co-amplification. Electrophoresis. 2009;30:1587-1593.
19. Ramos A, Santos C, Barbena E, et al. Validated primer set that prevents nuclear DNA sequences of mitochondrial origin co-amplification: a revision based on the New Human Genome Reference Sequence (GRCh37). Electrophoresis. 2011;32:782-783.
20. Accetturo M, Santamaria M, Lascaro D, et al. Human mtDNA site-specific variability values can act as haplogroup markers. Hum Mutat. 2006;27: 965-974.
21. Andrews RM, Kubacka I, Chinnery PF, et al. Reanalysis and revision of the Cambridge reference sequence for human mitochondrial DNA. Nat Genet. 1999;23:147.
22. Grasbon-Frodl EM, Kösel S, Sprinzl M, et al. Two novel point mutations of mitochondrial tRNA genes in histologically confirmed Parkinson disease. Neurogenetics. 1999;2:121-127.
23. Ban M, Elson J, Walton A, et al. Investigation of the role of mitochondrial DNA in multiple sclerosis susceptibility. PLoS One. 2008;3:e2891. Available at: http://www.plosone.org/article/info%3Adoi%2F10.1371% 2Fjournal.pone.0002891. Accessed January 15, 2013.
24. Salas A, Richards M, De la Fe T, et al. The making of the African mtDNA Landscape. Am J Hum Genet. 2002;71:1082-1111.
25. Cherry CL, Affandi JS, Imran D, et al. Age and height predict neuropathy risk in patients with HIV prescribed stavudine. Neurology. 2009;73: 315-320.
26. Keswani SC, Pardo CA, Cherry CL, et al. HIV-associated sensory neuropathies. AIDS. 2002;16:2105-2117.
27. Anderson PL, Kakuda TN, Lichtenstein KA. The cellular pharmacology of nucleoside- and nucleotide-analogue reverse-transcriptase inhibitors and its relationship to clinical toxicities. Clin Infect Dis.2004;38:743-753.
28. Phan V, Thai S, Choun K, et al. Incidence of treatment-limiting toxicity with stavudine-based antiretroviral therapy in Cambodia: a retrospective cohort study. PLoS One. 2012;7:e30647. Available at: http://www.plosone. org/article/info%3Adoi%2F10.1371%2Fjournal.pone.0030647. Accessed January 3, 2013.
29. Kamerman PR,Wadley AL, Cherry CL. HIV-associated sensory neuropathy: risk factors and genetics. Curr Pain Headache Rep. 2012;16:226-236.
30. Menezes CN, Maskew M, Sanne I, et al. A longitudinal study of stavudineassociated toxicities in a large cohort of South African HIV infected subjects. BMC Infects Dis. 2011;11:244. Available at: http://www.biomedcentral. com/1471-2334/11/244. Accessed March 14, 2013.
31. Wallace DC, Brown MD, Lott MT. Mitochondrial DNA variation in human evolution and disease. Gene. 1999;238:211-230.
32. Ballard JWO, Whitlock MC. The incomplete natural history of mitochondria. Mol Ecol. 2004;13:729-744.
33. Canter JA, Haas DW, Kallianpur AR, et al. The mitochondrial pharmacogenomics of haplogroup T: MTND2&z.ast;LHON4917G and antiretroviral therapy-associated peripheral neuropathy. Pharmacogenomics J. 2007;8:71-77.
34. Canter JA, Robbins GK, Selph D, et al. African mitochondrial DNA subhaplogroups and peripheral neuropathy during antiretroviral therapy. J Infect Dis. 2010;201:1703-1707.
35. Affandi JS, Price P, Imran D, et al. Can we predict neuropathy risk before stavudine prescription in a resource-limited setting? AIDS Res Hum Retroviruses. 2008;24:1281-1284.